Encompass Health Corp (EHC) · Aug 13, 2026 · New debt
$100M additional debt — $100M notes; ~$96.9M net proceeds used to repay revolver
Encompass Health added $100M of 5.875% notes due 2034, using nearly all proceeds to reduce revolver debt—more term funding, but incremental leverage.
The financing direction was already familiar, but this filing adds size. Encompass Health had previously disclosed a $500 million 5.875% notes offering intended partly to reduce revolver borrowings; this filing confirms an additional $100 million issuance on August 13, 2026. The incremental amount—not the general refinancing strategy—is the new information.
| Item | Filing figure |
|---|---|
| Additional notes issued | $100 million (Transaction description) |
| Coupon / maturity | 5.875% / 2034 (Transaction description) |
| Issue price | 98.75% of principal (Transaction description) |
| Net proceeds | Approximately $96.9 million (Transaction description) |
| Existing notes of same class | $500 million; total class becomes $600 million (Transaction description) |
| Use of proceeds | Repay part of revolving credit facility (Transaction description) |
This is largely a maturity-and-liquidity reshuffle, not fresh growth capital. Nearly all net proceeds go toward reducing the revolving credit facility, while the company takes on an equal amount of longer-dated senior notes. That should reduce reliance on floating or nearer-term revolver funding, but it does not meaningfully reduce gross debt and creates additional fixed interest expense. (Transaction description)
The economics are modestly less favorable than the original issue. The new notes were sold at 98.75% of face value, below the 100% price reported for the original $500 million offering, indicating a small issuance discount and somewhat higher effective borrowing cost than the coupon alone suggests. The filing does not provide a market consensus or a stated target for this additional borrowing, so a precise beat-or-miss comparison is unavailable.
Net read: incremental debt, offset by better funding duration. Relative to the previously known refinancing plan, the extra $100 million is a new balance-sheet commitment; relative to the likely goal of reducing revolver exposure, it is consistent with the existing strategy. The result is therefore mixed rather than a clean positive or negative surprise.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!